CERo Therapeutics (CERO) said Tuesday that the US Food and Drug Administration has granted orphan drug designation for its lead drug candidate, CER-1236, for acute myeloid leukemia.
Shares jumped over 220% as intraday trading volume advanced to over 51.2 million from a daily average of about 101,000.
Acurx Pharmaceuticals (ACXP) said its lead antibiotic candidate, ibezapolstat, is ready to advance to international phase 3 clinical trials to treat patients with C. difficile infection.
Shares soared over 130% as intraday trading volume surged to more than 309 million from a daily average of roughly 182,000.
Eli Lilly (LLY) said that it agreed to acquire Verve Therapeutics (VERV) for up to about $1.3 billion to advance gene-editing therapies for cardiovascular disease.
Verve shares soared 78%, with intraday trading volume of more than 72.5 million against a daily average of about 3.49 million.
Price: 22.04, Change: +15.18, Percent Change: +220.97
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。